Welcome to Santa Cruz Biotechnology!
SCBT Home
Home » Chemicals » IL-1 Inhibitors » Methotrexate hydrate: sc-215309

Methotrexate hydrate (CAS 133073-73-1)

(Based on popularity)

Application:A cell cycle arrest agent that inhibits DHFR and modulates inflammation
CAS Number:133073-73-1
Purity:≥99%
Molecular Weight:454.44 (anhydrous basis)
Molecular Formula:C20H22N8O5 H2O
Set Currency

 Ordering Information
Product NameCatalog #UnitPriceQtyAdd 
Methotrexate hydrate sc-215309 100 mg $123
Methotrexate hydrate sc-215309A 500 mg $517
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
Description
Methotrexate hydrate is the hydrated form of Methotrexate. Methotrexate is a cell cycle arresting agent with varying effects. Methotrexate has been reported to arrest the cell cycle in late G1/S thus leading to the inhibition of the synthesis of DNA, RNA, thymidylates, and proteins. The main mechanism of action is reported to involve the inhibition of enzymes involved in purine metabolism which leads to the accumulation of adenosine or the suppression of intercellular adhesion molecule expression by T cells. Additionally, this compound has been observed to inhibit DHFR. Methotrexate has also been shown to modulate inflammation by promoting adenosine release or inhibiting transmethylation reactions. Methotrexate was also noted to decrease IL-1 production in adherent splenic cells. Additionally offered as an anhydride, Methotrexate (sc-3507).
Technical Information
Appearance:powder
Physical State:Solid
Solubility:Insoluble in water.
Storage:Store at -20° C
Safety and Reference Information
Transport:UN 1544, Class 6.1, Packing group III
PubChem CID:165528
MDL Number:MFCD00150847
SMILES:CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
References
1. Richardson, V.B. 1994. Cytogenet. Cell Genet. 66: 126-128. PMID: 8287684 2. Pittman, S.M. 1994. Exp. Cell Res. 215: 263-272. PMID: 7982469 3. Huschtscha, L.I. 1996. Br. J. Cancer. 73: 54-60. PMID: 8554984 4. Parker, R. 2010. Postgrad Med J. 86: 208-211. PMID: 20354043 5. Fleisher, M. 1993. Ther Drug Monit. 15: 521-526. PMID: 8122287 6. Eckardt, J.R. 1996. Anticancer Drugs. 7: 41-46. PMID: 8862711 7. Cronstein, B.N. 1997. Rheum. Dis. Clin. North Am. 23: 739-755. PMID: 9361153
8. Rajagopalan, P.T., et al. 2002. Proc. Natl. Acad. Sci. U.S.A. 99: 13481-13486. PMID: 12359872
9. DiMartino, M.J., et al. 1987. Agents Actions. 21: 348-350. PMID: 3500597
SDS
Related Product Categories